Novotech announces transition of CEO role

You are here

Novotech announces transition of CEO role from Alek Safarian to John Moller, effective 23rd January 2017. Currently based in Novotech’s Singapore office, Dr Moller joined Novotech as Chief Operating Officer, Asia, in January 2014 and has overseen strong growth in Novotech’s Asian business.  He has been on company’s Board of Directors since August 2014. 

“John brings tremendous leadership to Novotech, and a proven track record of success. After 21 years in the role, I’m delighted that someone of John’s caliber will be taking over the CEO role and steering the next chapter of the company’s growth” said founding CEO, Alek Safarian. 

Dr Moller is a medical doctor by training with an MBA from University of Oxford. Prior to joining Novotech, Dr Moller held various senior positions, including as a management consultant with the Boston Consulting Group, and as Managing Director of IVF Australia, Queensland Fertility Group and the parent company Virtus Health. 

After stepping down from his current role, Mr Safarian will continue his close association with Novotech as a board member, together with  representatives of Mercury Capital. Dr Moller will relocate to Sydney, Australia prior to assuming the CEO role.